维得利珠单抗联合复方谷氨酰胺肠溶胶囊对溃疡性结肠炎患者的治疗效果

Clinical Study of Verderizumab Combined with Compound Glutamine Enteric-Soluble Capsules in Patients with Ulcerative Colitis

目的探讨维得利珠单抗联合复方谷氨酰胺肠溶胶囊治疗溃疡性结肠炎(UC)的效果。方法采用随机数表法将周口市中心医院2020年12月至2022年7月收治的102例UC患者分为两组,每组51例。对照组接受对症治疗并服用复方谷氨酰胺肠溶胶囊,研究组在对照组基础上使用维得利珠单抗。第14周观察治疗效果。对比两组临床疗效、肠黏膜屏障功能、氧化应激指标、外周血炎症因子。结果研究组总有效率高于对照组(P<0.05)。两组治疗后内毒素、D-乳酸、二胺氧化酶均低于治疗前(P<0.05),研究组治疗后上述指标均低于对照组(P<0.05)。两组治疗后丙二醛、过氧化脂质、活性氧簇均低于治疗前(P<0.05),研究组治疗后上述指标均低于对照组(P<0.05)。两组治疗后白细胞介素-4(IL-4)、IL-8、IL-17均低于治疗前(P<0.05),研究组治疗后上述指标均低于对照组(P<0.05)。对照组治疗前后Th1/Th2、Th17/Treg差异无统计学意义(P>0.05)。结论维得利珠单抗联合复方谷氨酰胺肠溶胶囊治疗UC可增强治疗效果,改善肠黏膜屏障功能,抑制氧化应激反应及炎症因子合成。

Objective To investigate the effect of vedolizumab combined with compound glutamine enteric-coated capsules in the treatment of ulcerative colitis(UC).Methods A total of 102 UC patients admitted to Zhoukou Central Hospital from December 2020 to July 2022 were selected as the research objects,and were divided into control group and study group by random number table method,with 51 cases in each group.The control group received symptomatic treatment and compound glutamine enteric-coated capsules,and the study group received vedolizumab on the basis of the control group.The therapeutic effect was observed in both groups at week 14.The clinical efficacy,intestinal mucosal barrier function,oxidative stress index,and peripheral inflammatory factors were compared between the two groups.Results The total effective rate of the study group was higher than control group(P<0.05).After treatment,endotoxin,D-lactic acid and diamine oxidase in both groups were lower than before treatment(P<0.05),and the above indexes in the study group were lower than control group(P<0.05).Malondialdehyde,lipid peroxide and reactive oxygen species were all lower in both groups after treatment than before treatment(P<0.05),and the above indexes in the study group were lower than control group after treatment(P<0.05).The levels of interleukin-4(IL-4),IL-8 and IL-17 in both groups after treatment were lower than before treatment(P<0.05),and those in the study group after treatment were lower than control group(P<0.05).Conclusion Vedolizumab combined with compound glutamine enteric-soluble capsules in the treatment of UC can enhance the therapeutic effect,improve the intestinal mucosal barrier function,and inhibit oxidative stress response.